| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.069 | 0.3 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.3 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.3 |